These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 20842682)

  • 1. Some essential clarifications: IQWiG comments on two critiques of the efficiency frontier approach.
    Dintsios CM; Gerber A
    Health Econ; 2010 Oct; 19(10):1139-41. PubMed ID: 20842682
    [No Abstract]   [Full Text] [Related]  

  • 2. IQWiG methods--a response to two critiques.
    Caro JJ; Nord E; Siebert U; McGuire A; McGregor M; Henry D; de Pouvourville G; Atella V; Kolominsky-Rabas P
    Health Econ; 2010 Oct; 19(10):1137-8. PubMed ID: 20842681
    [No Abstract]   [Full Text] [Related]  

  • 3. The efficiency frontier approach to economic evaluation: will it help German policy making?
    Brouwer WB; Rutten FF
    Health Econ; 2010 Oct; 19(10):1128-31. PubMed ID: 20641141
    [No Abstract]   [Full Text] [Related]  

  • 4. Sins of omission and obfuscation: IQWIG's guidelines on economic evaluation methods.
    Sculpher M; Claxton K
    Health Econ; 2010 Oct; 19(10):1132-6. PubMed ID: 20662107
    [No Abstract]   [Full Text] [Related]  

  • 5. The efficiency frontier approach to economic evaluation of health-care interventions.
    Caro JJ; Nord E; Siebert U; McGuire A; McGregor M; Henry D; de Pouvourville G; Atella V; Kolominsky-Rabas P
    Health Econ; 2010 Oct; 19(10):1117-27. PubMed ID: 20575151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Time for a common standard for cost-effectiveness in Europe?
    Jönsson B
    Eur J Health Econ; 2006 Dec; 7(4):223-4. PubMed ID: 17077979
    [No Abstract]   [Full Text] [Related]  

  • 8. [Comments by the Working Group for Methods of Economic Evaluation in Health Care (AG MEG) to IQWiG's Draft Guidelines "Methods for Assessment of the Relation of Benefits to Costs in the German Statutory Health Care System"].
    Krauth C; John J; Aidelsburger P; Brüggenjürgen B; Hansmeier T; Hessel F; Kohlmann T; Moock J; Rothgang H; Schweikert B; Seitz R; Wasem J;
    Gesundheitswesen; 2008 Jun; 70(6):e1-16. PubMed ID: 18661452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Valuing health technologies at NICE: recommendations for improved incorporation of treatment value in HTA.
    Goldman D; Lakdawalla D; Philipson TJ; Yin W
    Health Econ; 2010 Oct; 19(10):1109-16. PubMed ID: 20842680
    [No Abstract]   [Full Text] [Related]  

  • 10. Technology assessment in the German context.
    Drummond M
    Eur J Health Econ; 2007 Sep; 8 Suppl 1():S3. PubMed ID: 17619919
    [No Abstract]   [Full Text] [Related]  

  • 11. Regulatory space and the contextual mediation of common functional pressures: analyzing the factors that led to the German Efficiency Frontier approach.
    Klingler C; Shah SM; Barron AJ; Wright JS
    Health Policy; 2013 Mar; 109(3):270-80. PubMed ID: 23380191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic evaluation for pharmaceuticals in Germany.
    Jönsson B
    Eur J Health Econ; 2007 Sep; 8 Suppl 1():S1-2. PubMed ID: 17638033
    [No Abstract]   [Full Text] [Related]  

  • 13. Methods for determining cost-benefit ratios for pharmaceuticals in Germany.
    von der Schulenburg J; Vauth C; Mittendorf T; Greiner W
    Eur J Health Econ; 2007 Sep; 8 Suppl 1():S5-31. PubMed ID: 17582539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Why Do Health Economists Promote Technology Adoption Rather Than the Search for Efficiency? A Proposal for a Change in Our Approach to Economic Evaluation in Health Care.
    Scotland G; Bryan S
    Med Decis Making; 2017 Feb; 37(2):139-147. PubMed ID: 27317437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Health economics as the basis for the synthesis of efficiency and financial soundness in statutory health insurance].
    Straub C
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2006 Jan; 49(1):73-80. PubMed ID: 16333646
    [No Abstract]   [Full Text] [Related]  

  • 16. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current technology assessment programs/procedures.
    McDonough R
    J Laparoendosc Surg; 1993 Aug; 3(4):395-7. PubMed ID: 8268513
    [No Abstract]   [Full Text] [Related]  

  • 18. [More care for a limited budget; a case for a better use of the efficiency criteria].
    Rutten FF; Brouwer WB
    Ned Tijdschr Geneeskd; 2002 Nov; 146(47):2254-8. PubMed ID: 12481524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How should cost-effectiveness analysis be used in health technology coverage decisions? Evidence from the National Institute for Health and Clinical Excellence approach.
    Williams I; Bryan S; McIver S
    J Health Serv Res Policy; 2007 Apr; 12(2):73-9. PubMed ID: 17407655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cost-effectiveness evaluation of drugs: multidisciplinary collaboration and transparency are key].
    Mueller EA; Kirch W
    Med Klin (Munich); 2008 Oct; 103(10):712-6. PubMed ID: 18936896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.